A solid surfactant cosmetic composition includes (i) insoluble vegetable fibre, insoluble fruit fibre or mixture thereof; (ii) surfactant; and (iii) hydrocolloid. The solid surfactant cosmetic composition is prepared by dehydrating a liquid composition. The liquid composition includes (i) a vegetable pulp containing insoluble vegetable fibre, a fruit pulp containing insoluble fruit fibre or a mixture thereof, wherein the vegetable pulp, fruit pulp or mixture thereof is in an amount of 55 to 99 wt. %; (ii) surfactant in an amount of 0.9 to 40 wt. %; and (iii) hydrocolloid in an amount of 0.1 to 15 wt. %, the amounts being based on the total combined amount of pulp, surfactant and hydrocolloid.

Custom formulation systems include a user input device and a dispenser having a cabinet, a bead assembly, a fluid formulation assembly, and a mixing area. The bead assembly dispenses a plurality of beads containing a first cosmetic formulation, and is one of a plurality of bead assemblies located within the cabinet. The plurality of bead assemblies has a vertically organized configuration. The fluid formulation assembly is configured to dispense a second cosmetic formulation in flowable fluid form, and is one of a plurality of fluid formulation assemblies located within the cabinet. The mixing area is located within the cabinet and configured to receive at least one bead from the bead assembly and the second cosmetic formulation in flowable fluid form from the fluid formulation assembly. The vertically organized bead assemblies, the fluid formulation assemblies, and the mixing area are positioned adjacent to a first side of the cabinet.

Custom formulation systems include a user input device and a dispenser having a cabinet, a bead assembly, a fluid formulation assembly, and a mixing area. The bead assembly dispenses a plurality of beads containing a first cosmetic formulation, and is one of a plurality of bead assemblies located within the cabinet. The plurality of bead assemblies has a vertically organized configuration. The fluid formulation assembly is configured to dispense a second cosmetic formulation in flowable fluid form, and is one of a plurality of fluid formulation assemblies located within the cabinet. The mixing area is located within the cabinet and configured to receive at least one bead from the bead assembly and the second cosmetic formulation in flowable fluid form from the fluid formulation assembly. The vertically organized bead assemblies, the fluid formulation assemblies, and the mixing area are positioned adjacent to a first side of the cabinet.

The purpose of the present invention is to newly provide a method with which it is possible to appropriately evaluate the protective effect of an external preparation for skin such as a sunscreen cosmetic, particularly to evaluate how a UV-ray protective effect is affected by heat. This evaluation method is characterized by including (1) a step for forming a coating film of an external preparation for skin on a substrate, (2) a step for heat-treating the coating film of the external preparation for skin, and (3) a step for measuring the UV-ray protective effect of the heat-treated coating film of the external preparation for skin. The heat treatment is preferably carried out for at least one minute at a temperature of 30-70 C. The step for measuring the UV-ray protective effect preferably includes at least one selected from testing methods that involve comparing some kind of UV-ray protective effect with SPF measurement, UVAPF or PFA measurement, critical wavelength measurement, absorbance measurement, and transmittance measurement. This evaluation method can also be performed in vivo or in vitro.

The present invention relates to the use of turbine mixing during enzymatic hydrolysis of aquatic protein from species such as fish, aquatic mammals, crustaceans and/or mollusks, to obtain high quality aquatic protein hydrolysates, having very low oxidation, improved organoleptic profile and improved biological activity of interest, for human consumption and cosmetics. The turbine mixing can inhibit oxidation during hydrolysis, contribute to an increase in the bio-activity and decrease the bitter taste of the final product. The process can vary in starting material, pre-treatment, type and amount of enzyme, hydrolysis conditions, time, degree of hydrolysis and post-treatment.

The present invention relates to the use of turbine mixing during enzymatic hydrolysis of aquatic protein from species such as fish, aquatic mammals, crustaceans and/or mollusks, to obtain high quality aquatic protein hydrolysates, having very low oxidation, improved organoleptic profile and improved biological activity of interest, for human consumption and cosmetics. The turbine mixing can inhibit oxidation during hydrolysis, contribute to an increase in the bio-activity and decrease the bitter taste of the final product. The process can vary in starting material, pre-treatment, type and amount of enzyme, hydrolysis conditions, time, degree of hydrolysis and post-treatment.

Described herein is a process for preparing a stable perfuming composition including a perfume oil, a viscosifying agent including tricyclodecanedimethanol alcohol, and a perfumery carrier including dipropylene glycol.

Described herein, are personal care compositions comprising a cleanser base comprising at least one cleanser selected from a soap and a surfactant; and an effective amount of an antibacterial system comprising a combination of phenoxyethanol and piroctone, or a salt thereof. Methods of making and using these compositions are also described.

A library of heterocyclic compounds has been screened to identify particular compounds that have high inhibitory capacity for the Bcl family of regulatory proteins. Compounds identified as Bcl antagonists have been further screened to select pharmaceutical agents with both high potency and high specificity for eliminating senescent cells in comparison with replicative or quiescent cells of the same tissue type. Particular structures are identified in this disclosure that eliminate senescent cells with an EC.sub.50 in the nanomole range and a specificity around or above 100-fold. In accordance with this invention, heterocyclic compounds provided in this disclosure can be formulated for the treatment of a range of age-related conditions caused or mediated by senescent cells. Such conditions are exemplified by ophthalmic conditions, pulmonary conditions, and osteoarthritis.

A library of heterocyclic compounds has been screened to identify particular compounds that have high inhibitory capacity for the Bcl family of regulatory proteins. Compounds identified as Bcl antagonists have been further screened to select pharmaceutical agents with both high potency and high specificity for eliminating senescent cells in comparison with replicative or quiescent cells of the same tissue type. Particular structures are identified in this disclosure that eliminate senescent cells with an EC.sub.50 in the nanomole range and a specificity around or above 100-fold. In accordance with this invention, heterocyclic compounds provided in this disclosure can be formulated for the treatment of a range of age-related conditions caused or mediated by senescent cells. Such conditions are exemplified by ophthalmic conditions, pulmonary conditions, and osteoarthritis.